Need help choosing?
Login

Tag: GLP-1

  • Retatrutide: Stop Chasing Research Chemicals

    Retatrutide: Stop Chasing Research Chemicals

    Retatrutide may become a major obesity drug. But for most people chasing it online especially for modest weight loss, inflammation, or general metabolic optimization, it’s usually the wrong tool for the job.

    Retatrutide is an impressive piece of pharmacology: a triple hormone receptor agonist targeting GLP-1, GIP, and the glucagon receptor (GCGR). In early obesity trials, that three lever design produced striking weight loss results. It’s easy to see why the internet is fascinated.

    But medicine isn’t a contest for the biggest number on a scale. The real question isn’t, What’s the strongest drug? It’s: What is the lowest intensity, highest certainty intervention that reliably achieves the goal with an acceptable risk profile?

    That principle, minimum effective intensity, matters even more when people are discussing research use, investigational products outside clinical trials. Outside trials, many of the normal safety rails aren’t there: standardized sourcing, established monitoring patterns, and mature clinical guidance.

    Define the health goal before you pick the GLP-1

    Most people reach for retatrutide because they want one (or more) of these outcomes:

    • Appetite control and modest fat loss
    • Weight loss plus improved glucose / insulin resistance
    • Inflammation reduction, vascular health, organ protection, or cardiometabolic risk reduction
    • Severe obesity where maximum effect is the goal

    Those are not the same job. And drugs that look similar on social media can behave very differently in practice. When you skip this step and jump straight to “the strongest,” you end up with a common modern mistake: treating intensity as precision.

    Why Retatrutide is the sledgehammer by design

    Retatrutide isn’t just tirzepatide plus a little extra. It is designed to chase the upper limit of effect. GLP-1 and GIP primarily influence appetite, satiety, and incretin physiology, reducing energy intake and improving glucose dynamics. Retatrutide’s third mechanism, glucagon receptor (GCGR) agonism, is different. GCGR is a lever that can shift fuel handling and energy expenditure. That’s one reason retatrutide is being studied as a high ceiling obesity therapy.

    That extra lever is also where complexity tends to show up. In the phase 2 obesity trial, the study reported increases in heart rate. Outside the trial setting, many people also track wearables (resting heart rate, HRV). Wearable data is not definitive science, but it’s a real-world reminder that more physiologic force can show up in ways people notice.

    The point is not that retatrutide is “bad.” The point is that triple agonism is not a free upgrade. More levers means more variables, and more variables mean more ways for tradeoffs to emerge. If you don’t need ceiling chasing force, the rationale for accepting ceiling chasing complexity is weak.

    If the goal is inflammation or risk reduction, GLP-1 is the direct lever

    A major driver of public interest right now isn’t just weight loss. It’s the growing conversation about benefits beyond weight, often bundled under terms like inflammation reduction, vascular function, organ protection, and cardiometabolic risk reduction.

    If you want to discuss those benefits in a grounded way, the most coherent anchor is GLP-1 receptor biology. GLP-1 based therapies have been described in the literature as having anti-inflammatory actions across tissues, with effects that may be partly weight-loss dependent and partly weight loss independent.

    The practical takeaway isn’t to oversell that biology. It’s to match the tool to the target: If your primary objective is GLP-1 linked downstream effects, the most rational approach is to use a therapy that directly and predictably activates GLP-1, without adding receptor activation you don’t need for that outcome.

    That is the sledgehammer problem in plain language: you don’t reach for a maximum-intensity, multi-axis drug to do a job that appears largely GLP-1-mediated.

    Semaglutide is often the right tool when GLP-1 biology is the job

    Semaglutide is clean, single axis pharmacology: GLP-1 receptor agonism. That simplicity is a feature when your goal is primarily:

    • appetite regulation
    • predictable titration
    • a large evidence base and well-characterized side effects
    • GLP-1–linked cardiometabolic effects

    Semaglutide also has clinical signals that align with the inflammation conversation. Exploratory analyses from the STEP trials reported reductions in C-reactive protein(CRP) versus placebo in adults with overweight/obesity consistent with an anti-inflammatory signal.

    This is where many people get misled online: they confuse more receptors with more of the effect they want. When the intended effect is GLP-1-mediated, direct often matters more than maximal.

    Tirzepatide is often the right tool when you need broader metabolic leverage

    Tirzepatide targets two receptors GLP-1 and GIP without adding the glucagon axis. That matters because many people aren’t just trying to eat less. They are trying to change the metabolic backdrop: insulin resistance, dysglycemia risk, and broader cardiometabolic signals.

    Tirzepatide is often the better match when the job includes:

    • obesity plus clear insulin resistance
    • prediabetes risk or type 2 diabetes physiology
    • the need to move multiple levers at once (weight plus glucose biology)

    Put simply: when the goal is a broader metabolic reset, tirzepatide is often the most efficient, evidence supported two-lever option among currently approved therapies, without adding the third lever of glucagon receptor agonism.

    Where retatrutide fits (and where it usually doesn’t)

    It’s worth acknowledging: retatrutide may become an important therapy for select patients, particularly those with severe obesity and high cardiometabolic risk who truly need a ceiling chasing strategy. The phase 2 results are why clinicians are watching it closely. But that is a narrower lane than how retatrutide is discussed online.

    For most people, the biggest issue isn’t receptor theory, it’s practical reality. Retatrutide is investigational, not broadly approved as a standard prescribable medication. That means the usual infrastructure that protects patients routine prescribing patterns, standardized supply chains, mature monitoring guidance is not the same as it is for approved therapies.

    So the risk equation changes. If you don’t need ceiling-level intensity, the incremental benefit of chasing the ceiling is often small, while the potential downsides are real: more variability in product and dosing practices, side effects that are harder to anticipate outside trials, and inadequate monitoring.

    Put plainly: Ceiling chasing should require a ceiling level indication.

    Is glucagon (GCGR) activation meaningful at low dose?

    This question matters because a lot of research use behavior centers around micro-dosing. Retatrutide is a triple agonist, so it can engage GCGR. But it’s also reported to be much more potent at GIPR than at GCGR. It’s reasonable to think of low dose retatrutide as behaving more like a strong incretin than a uniquely glucagon/energy expenditure drug.

    In other words:

    • At lower doses, outcomes may overlap substantially with established incretin therapies, especially tirzepatide.
    • Retatrutide’s distinguishing third receptor advantage appears most relevant at higher exposures, where separation in weight loss becomes clearer.
    • We still lack definitive mechanistic human data proving GCGR activation is meaningfully additive at micro/low doses.

    So if someone is pursuing low dose retatrutide because they believe they’re getting a unique glucagon advantage, they may be overestimating what that third lever is actually contributing at that exposure.

    The simplest decision rule

    Before you chase a molecule, answer one question:

    What job are you trying to do?

    • If the job is primarily inflammation/risk reduction and GLP-1 biology is the plausible driver, start with a GLP-1-forward strategy (often semaglutide).
    • If the job is broader metabolic leverage, weight plus insulin resistance / glucose dynamics, tirzepatide is often the more coherent match.
    • If the job truly requires maximum effect for severe obesity, retatrutide may become a strong option, but that’s a specific lane, not a default upgrade.

    Escalate intensity only when the indication justifies it.

    References

    Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023. Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

    Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. PubMed record (abstract + indexing). 2023. Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

    Wong CK, et al. Anti inflammatory actions of glucagon-like peptide-1–based therapies. Journal of Clinical Investigation. 2025. (Review of direct and indirect anti-inflammatory effects and mechanisms of GLP-1 medicines, including areas of uncertainty.) Link: https://pubmed.ncbi.nlm.nih.gov/41178710/

    Verma S, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomized, double-blind, placebo-controlled, phase 3 trials. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea in Adults with Obesity. New England Journal of Medicine. 2024 Link: https://pubmed.ncbi.nlm.nih.gov/36467859/

    Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea in Adults with Obesity. New England Journal of Medicine. 2024. Link: https://www.nejm.org/doi/10.1056/NEJMoa2404881 Link: https://www.nejm.org/doi/10.1056/NEJMoa2404881

    Site Links

    Compounded Semaglutide
    Compounded Tirzepatide
    Microdose GLP-1
    Microdose GLP-1 + GIP
    Sermorelin
    Testosterone
    Erectile Dysfunction
    Hair Loss
    NAD
  • Sermorelin Peptide for Muscle Loss with Patients on GLP-1s

    Sermorelin Peptide for Muscle Loss with Patients on GLP-1s

    GLP-1 medications like semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) have transformed medical weight loss. Many patients experience meaningful, sustained fat loss, often for the first time. But as the scale drops, a common concern is how much muscle/lean mass is being lost as well.

    In general, weight loss, especially rapid or significant weight loss, almost always includes some loss of lean mass, which includes muscle, water, organs, and connective tissue. Clinical trials of GLP-1 medications confirm that while on GLP-1 therapy most weight loss is fat, but lean mass can be a large portion of the loss because of how rapidly patients shed the pounds.

    Why muscle loss can happen on GLP-1s

    GLP-1s suppress appetite and often slow gastric emptying, particularly early in treatment. Many patients eat far fewer calories than before, sometimes unintentionally. When calorie intake drops quickly, the body pulls energy from both fat and lean tissue. As total caloric intake falls, protein intake often falls as well. Smaller meals, food aversions, and early satiety can lead to lower protein intake unless patients are intentional. Insufficient protein during weight loss increases the risk of losing lean mass rather than fat alone.

    Another contributing factor is reduced mechanical demand. As body weight decreases, muscles are under less load in daily life. Without resistance training, the body may interpret this as a signal that less muscle is required. This pattern is not unique to GLP-1s and is seen across many forms of weight loss.

    As awareness of this issue grows, patients and clinicians are exploring strategies to preserve muscle while continuing the metabolic benefits of GLP-1 therapy. One therapy that often enters the conversation is Sermorelin.

    What is Sermorelin?

    Sermorelin is a synthetic peptide that mimics growth hormone–releasing hormone (GHRH), a signal produced by the brain that stimulates the pituitary gland to release growth hormone (GH). Rather than supplying growth hormone directly, sermorelin works upstream in the GH axis: Sermorelin → pituitary GH release → increased IGF-1 signaling.

    Growth hormone and insulin-like growth factor-1 (IGF-1) influence tissue repair,  metabolism, and body composition by stimulating fat breakdown (lipolysis) and decreasing fat storage (lipogenesis) in fat cells (adipocytes) and body. GH secretion naturally declines with age, obesity, and poor sleep, factors common in patients seeking GLP-1 therapy.

    Potential benefits of Sermorelin during GLP-1 weight loss

    1. Supporting muscle quality, not just size

    Muscle health isn’t only about how much muscle you have—it also includes strength, recovery, mitochondrial function, and neuromuscular coordination.

    Growth hormone plays a role in muscle protein turnover and repair, particularly when combined with resistance training. In studies of GHRH analogs in adults, activation of the GH axis was associated with increases in lean body mass.

    Sermorelin may help preserve muscle quality and functional strength, even if some lean mass loss still occurs during weight reduction. Importantly, GH does not directly build muscle like anabolic steroids. Instead, it may create a more supportive internal environment for muscle maintenance when proper nutrition and training are present.

    2. Improved recovery capacity during weight loss

    GLP-1–associated weight loss can feel physically demanding; lower energy intake, reduced training tolerance, and fatigue during dose escalation are common.

    Growth hormone plays a role in tissue repair and recovery, including connective tissue remodeling. Some patients report improved recovery and exercise tolerance with GH-axis stimulation, which could help maintain muscle by allowing more consistent resistance training.

    3. Indirect benefits through sleep quality

    A major daily pulse of growth hormone occurs shortly after sleep onset and is closely linked to slow-wave (deep) sleep. Poor sleep impairs muscle recovery, worsens insulin sensitivity, and increases fatigue.

    Sermorelin is often reported to improve sleep continuity or depth. Better sleep could indirectly support muscle recovery, training adherence, and overall metabolic health. Any muscle-preserving strategy that improves sleep deserves consideration, even if the effect is indirect.

    4. Favoring fat loss over lean loss (nutrient partitioning)

    Growth hormone has known effects on lipolysis (fat breakdown) and free-fatty-acid mobilization. GH-axis stimulation shifts weight loss toward fat mass rather than lean mass.

    This concept, known as nutrient partitioning, is one reason pharmaceutical companies are actively developing muscle-preserving agents to pair with GLP-1 therapies. While sermorelin is not one of these new investigational drugs, the theory aligns with why this combination is being explored.

    5. Age-related considerations

    GH secretion declines naturally with age. Patients over 40, postmenopausal women, and individuals with long-standing obesity may begin GLP-1 therapy with lower baseline GH output.

    Sermorelin could partially offset this decline, potentially narrowing the gap in muscle-preservation outcomes between younger and older patients during weight loss. This does not mean Sermorelin “reverses aging,” but it may address a specific physiologic limitation.

    Here’s the most important takeaway:

    There is no direct clinical trial proving that Sermorelin prevents muscle loss specifically in patients using GLP-1 medications.

    What we do have includes:

    • robust data showing GLP-1s reduce lean mass alongside fat loss
    • studies showing GH-axis stimulation with peptides like Sermorelin can influence body composition (increased lean mass and increased lipolysis)
    • growing industry focus on muscle preservation as a recognized unmet need

    Risks and limitations to understand

    Sermorelin does not replace protein intake or resistance training.

    GH-axis stimulation can cause side effects such as fluid retention, joint discomfort, tingling or numbness, headaches, and changes in glucose handling. IGF-1 levels should be monitored, more is not always better. Quality and sourcing matter significantly, and medical supervision is essential.

    What matters for preserving muscle on GLP-1s

    Whether or not Sermorelin is used, the most effective muscle-preserving tools remain:

    • Resistance training (2–4 times per week)
    • Intentional protein intake
      • A practical way many clinicians guide patients is to think in terms of up to 1 gram of protein per pound of goal body weight per day. This is not a requirement, and most patients will not consistently reach this number. However, using this target as a mental framework often results in patients consuming enough protein to support muscle preservation, even when actual intake falls well below 1 g/lb.
    • Tracking strength and function, not just scale weight.

    Sermorelin and GLP-1s bottom line

    Sermorelin is discussed for muscle preservation on GLP-1s. For patients who are strength-training, prioritize protein, and work with knowledgeable clinicians, it is a reasonable adjunct to explore. But remember, the foundation remains unchanged: Muscle is preserved by use, fuel, and recovery, not by peptides alone.

    References

    1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. Link: https://pubmed.ncbi.nlm.nih.gov/33567185/
    2. Wilding JPH, et al. Impact of Semaglutide on Body Composition: STEP-1 Exploratory DXA Analysis. 2021. Link: https://pubmed.ncbi.nlm.nih.gov/33567185/
    3. Look M, et al. Body Composition Changes with Tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025. Link: https://pubmed.ncbi.nlm.nih.gov/39996356/
    4. Khorram O, et al. Long-Term GHRH Analog Administration in Older Adults. J Clin Endocrinol Metab. 1997. Link: https://pubmed.ncbi.nlm.nih.gov/9141536/
    5. Walker RF, et al. Sermorelin as an Alternative to GH Therapy. 2006. Link: https://pubmed.ncbi.nlm.nih.gov/18046908/
    6. Reuters. Regeneron reports muscle-preserving effects with experimental obesity drug. 2025. Link: https://www.reuters.com/business/healthcare-pharmaceuticals/regenerons-weight-loss-drug-helps-preserve-muscle-mass-study-2025-06-02/

    Precision Telemed Clickable Links
    Compounded Tirzepatide
    Compounded Semaglutide
    Sermorelin Peptide
    NAD+ Injections
    Testosterone Replacement Therapy
    Hair Loss
    Erectile Dysfunction

  • GLP-1 and NAD+

    GLP-1 and NAD+

    Feeling Drained During Your GLP-1 Weight-Loss Journey? Here’s How NAD⁺ Injections Might Help You Feel Like Yourself Again

    Many patients start GLP-1 medications with clear goals. Better health, steady weight loss, and renewed confidence. Then, a few weeks in, they notice something they didn’t expect: exhaustion. Patients notice that they are finally losing weight but they feel like they’re “running on empty.”

    That kind of fatigue is more common than most people think. As clinicians, we’ve seen it time and again, especially during the first few months on GLP-1 medications, such as semaglutide or tirzepatide. That being said, there are ways to support energy without derailing progress. One promising tool is NAD⁺ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy production.

    Let’s dive in to why fatigue can creep in during GLP-1 therapy, what NAD⁺ actually does inside your cells, and why NAD⁺ injections are gaining attention among people who want to feel energized again.

    Why Fatigue Happens with GLP-1 Weight-Loss Therapy

    GLP-1 receptor agonists work by slowing digestion and decreasing appetite, so you naturally eat less (Wilding et al. 989). When calorie intake drops, your body has to adapt; essentially, it starts running on stored energy instead of constant fuel. This metabolic shift is healthy, but it can make you feel sluggish, foggy, or mentally flat for a while.

    We also see a few other contributors:

    • Reduced calories and protein: muscles can temporarily lose fuel.
    • Mild dehydration: appetite changes often mean lower fluid intake.
    • Micronutrient shifts: your body is burning through reserves.
    • Mitochondrial slowdown: the “power plants” in your cells produce less ATP when nutrients drop (Yoshino et al. 1225).

    That last point is where NAD⁺ becomes especially interesting.

    Meet NAD⁺: Your Cells’ Energy Middleman

    Inside every cell, NAD⁺ helps turn food into ATP, the molecule that literally powers movement, focus, and repair (Bogan and Brenner 118). Think of it as a universal battery connector. Without enough NAD⁺, the entire energy chain sputters.

    Levels of NAD⁺ naturally decline with age and stress (Verdin 1210). Rapid weight loss, reduced caloric intake, and hormonal changes can accelerate that dip. When NAD⁺ drops, so does mitochondrial performance, leaving you with slower metabolism, mental fog, and that mid-day crash we hear about so often.

    Supporting NAD⁺ levels is about more than “feeling awake.” It’s about helping your cells produce energy efficiently again, so your weight-loss plan feels sustainable instead of draining.

    How NAD⁺ Injections Work

    NAD⁺ occurs naturally in the body, but oral supplements can be tricky, much of it breaks down in the gut before it ever reaches the bloodstream. Injectable NAD⁺, on the other hand, delivers it directly for faster and more complete absorption (Trammell et al. 12948).

    It isn’t a caffeine rush or a stimulant hit. Patients describe it more like having their “battery” quietly recharged, a steadier kind of energy that builds over several days.

    Reported benefits include:

    • More consistent daytime energy
    • Sharper concentration and mental clarity
    • Easier post-workout recovery
    • Less of the “afternoon crash” feeling

    The mechanism makes sense: improving mitochondrial function through NAD⁺ replenishment allows every cell, from brain to muscle, to do its job more efficiently (Stein and Imai 1813).

    What the NAD+ Research Tells Us

    Scientific studies show that boosting NAD⁺; either through precursors such as nicotinamide riboside or via direct supplementation; can improve mitochondrial health, reduce oxidative stress, and support metabolic balance (Cantó et al. 840; Gomes et al. 1626).

    In one study, NAD⁺ precursors increased muscle insulin sensitivity in prediabetic women (Yoshino et al. 1228). Others found improved cellular resilience and better energy metabolism during caloric restriction (Rajman et al. 505). There aren’t yet large trials on GLP-1 users specifically, but the biology lines up. Restoring NAD⁺ gives the body more of what it needs to adapt to weight loss gracefully. It’s a complementary therapy, not a replacement; GLP-1 targets appetite and insulin regulation, NAD⁺ supports the energy systems behind them.

    Why So Many Patients Ask About NAD+

    Typically, patients on GLP-1s often say, “I finally have control over my hunger, but I miss my old energy.” That’s where NAD⁺ can help bridge the gap. It supports sustainable vitality without relying on stimulants or sugar.

    Unlike quick-fix solutions, NAD⁺ injections work at the cellular level. They don’t just mask fatigue; they help your body restore its natural rhythm (Rajman et al. 508). For anyone balancing work, family, and weight-loss goals, that steadier kind of energy can make all the difference.

    What to Expect from NAD+ Therapy

    Treatment plans vary, but most patients start with a series of injections administered by a licensed provider. Each session usually takes less than an hour. Energy improvements tend to appear gradually over several sessions as NAD⁺ levels stabilize.

    Some describe it as “having my spark back.” Others simply notice fewer dips in focus or mood. If you’re using GLP-1 medication, your clinician will tailor dosing to complement your therapy and avoid overlap with other metabolic agents.

    Who Might Benefit Most

    NAD⁺ therapy may be particularly helpful for:

    • Patients using GLP-1s who experience persistent fatigue
    • Individuals adjusting to lower calorie intake
    • Those maintaining weight loss and looking for better recovery
    • Anyone under physical or cognitive stress

    It’s not about perfection; it’s about feeling capable and balanced while your body transforms.

    A Science-Backed Way to Support Your Energy

    Weight-loss success should feel empowering, not exhausting. If you’ve been feeling drained on a GLP-1, ask your Precision Telemed provider whether NAD⁺ injections could fit into your care plan.

    Our team focuses on evidence-based, patient-centered therapies that help you achieve lasting results, and feel your best while doing it. You’ve done the hard part by starting; NAD⁺ might just help you finish strong.

    References

    Bogan, K. L., and C. Brenner. “Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAD⁺ Precursor Vitamins in Human Nutrition.” Annual Review of Nutrition, vol. 28, 2008, pp. 115–130. Link: Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition – PubMed

    Cantó, C., et al. “The NAD⁺ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity.” Cell Metabolism, vol. 15, no. 6, 2012, pp. 838–847. Link: https://pubmed.ncbi.nlm.nih.gov/22682224/

    Gomes, A. P., et al. “Declining NAD⁺ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging.” Cell, vol. 155, no. 7, 2013, pp. 1624–1638.
    Rajman, L., et al. “NAD⁺ as a Metabolic Link between DNA Damage, Aging, and Disease.” Cell Metabolism, vol. 27, no. 3, 2018, pp. 502–514. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC4076149/

    Stein, L. R., and S. Imai. “Specific Ablation of Nampt in Adult Neural Stem Cells Recapitulates the Age-Associated Decline in Neural Stem Cell Function.” Genes & Development, vol. 28, 2014, pp. 1812–1823. Link: https://pubmed.ncbi.nlm.nih.gov/24811750/

    Trammell, S. A. J., et al. “Nicotinamide Riboside Is Uniquely and Orally Bioavailable in Mice and Humans.” Nature Communications, vol. 7, 2016, Article 12948. Link: https://www.nature.com/articles/ncomms12948

    Verdin, E. “NAD⁺ in Aging, Metabolism, and Neurodegeneration.” Science, vol. 350, no. 6265, 2015, pp. 1208–1213. Link: https://pubmed.ncbi.nlm.nih.gov/26785480/

    Wilding, J. P. H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, vol. 384, 2021, pp. 989–1002. Link: https://pubmed.ncbi.nlm.nih.gov/33567185/

    Yoshino, J., et al. “Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women.” Science, vol. 372, 2021, pp. 1224–1229. Link: https://pubmed.ncbi.nlm.nih.gov/33888596/

    Yoshino, J., et al. “SIRT1 Activation Mediates the Beneficial Effects of Resveratrol on Mitochondrial Function.” Cell Metabolism, vol. 14, no. 5, 2011, pp. 612–620. Link: https://pubmed.ncbi.nlm.nih.gov/22560220/

    Precision Telemed Clickable Links
    Compounded Tirzepatide
    Compounded Semaglutide
    Sermorelin Peptide
    NAD+ Injections
    Testosterone Replacement Therapy
    Hair Loss
    Erectile Dysfunction

  • Compounded Tirzepatide: A Dual-Action Peptide

    Compounded Tirzepatide: A Dual-Action Peptide

    Tirzepatide is the first medication in a new drug class sometimes known as a twincretin, because it targets two hormone receptors that regulate insulin and metabolism. Although tirzepatide was initially developed to treat type 2 diabetes, it has demonstrated significant effects on weight loss and has been rapidly adopted under the brand names Mounjaro (for diabetes) and Zepbound (for obesity).

    The high demand for these drugs has resulted in shortages, so many patients and providers have turned to compounded tirzepatide, created at specialty pharmacies. If you are considering your options, it is essential to understand how tirzepatide works and the differences between the FDA-approved and compounded versions of this medication.

    What Is Tirzepatide Peptide?

    Tirzepatide is a synthetic peptide that consists of 39 amino acids. Amino acids are the building blocks of proteins. Peptides are short amino acid chains. They serve many important bodily functions. In addition to being the foundation of all proteins, they are involved in the immune system, tissue repair, signal transmission between cells, and the regulation of cellular function.

    Tirzepatide mimics the action of two natural hormones released by intestinal cells: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones, known as incretins, are secreted after eating and play critical roles in regulating appetite, stimulating the release of insulin, and processing carbohydrates and fats.

    Tirzepatide acts on both GLP-1 and GIP receptors, which increase insulin secretion, slow stomach emptying, decrease appetite, and improve glucose control.

    Insulin, Glucagon, and Blood Sugar Control

    Maintaining a healthy blood sugar balance depends on the coordination of insulin and glucagon. These two peptide hormones, secreted by the pancreas, regulate blood sugar by acting on various cells and tissues throughout the body.

    Insulin

    • Insulin signals cells to take up glucose from the blood and convert it to glycogen, a form of carbohydrate storage in the liver and skeletal muscle.
      • Glycogen is composed of chains of glucose molecules that can be rapidly broken down into glucose when the body requires energy.
    • Insulin also stimulates the uptake of glucose by fat cells, which then synthesize fat from glucose for longer-term storage.
    • Insulin lowers blood sugar.

    Glucagon

    • Glucagon, by contrast, is released when blood sugar is low. I
    • Glucagon signals the liver to break down glycogen into glucose for energy.
    • Glucagon also stimulates glucose production from non-carbohydrate sources such as amino acids, a process known as gluconeogenesis.
    • Glucagon typically increases blood sugar.

    How Does Tirzepatide Peptide Work?

    Tirzepatide shifts the balance of insulin and glucagon toward greater insulin action and reduced glucagon release, leading to improved glucose control and decreased hunger.

    Tirzepatide’s dual action sets it apart from medications like semaglutide (Wegovy or Ozempic):

    GLP-1 activity

    • Increases the number of pancreatic betal cells
    • Stimulates insulin secretion by beta cells
    • Increases insulin sensitivity
    • Increases clearance of triglycerides (a type of cholesterol)
    • Breaks up fats
    • Delays stomach emptying
    • Acts on the brain’s appetite centers to promote fullness

    GIP activity

    • Mainly acts on pancreas
    • Decreases glucagon release by the pancreas
    • Increases insulin release
    • Promotes fat storage
    • Supports the synthesis of glycogen

    People with type 2 diabetes often have abnormally low levels of GIP, or their pancreatic cells do not respond normally to GIP to release an adequate amount of insulin with food intake. People with obesity often have elevated GIP levels, since dietary fat stimulates GIP secretion.

    The combined action of tirzepatide makes it highly effective in lowering hemoglobin A1C in individuals with diabetes and supporting sustained weight loss in those with obesity.

    Manufacturing Shortages Led to Compounded Tirzepatide

    Although Mounjaro is FDA-approved for the management of type 2 diabetes, doctors also prescribe it “off-label” for weight loss. Off-label prescribing refers to the use of a medication for a purpose other than its original FDA-approved indication. Zepbound is the same drug, but it is FDA-approved for weight loss in people with obesity. Neither drug currently has a generic version.

    Due to the high demand for the drugs, a shortage of tirzepatide began in 2022 and lasted until December 2024. During this period, the FDA added tirzepatide to its drug shortage list and worked with the manufacturer to increase production. Although the shortage has largely been resolved, occasional supply issues persist at some pharmacies.

    When a drug is on the shortage list, state-licensed compounding pharmacies are permitted to prepare compounded drugs that closely match the FDA-approved product. The active ingredient remains the same, although a compounding pharmacy may add or remove non-essential ingredients.

    Compounded medications may also be prepared to remove allergens, create a liquid form for patients who cannot swallow pills, or adjust the dose strength to meet a specific patient’s needs.

    What Is Compounded Tirzepatide?

    Compounded tirzepatide has the same active ingredient as the FDA-approved brands. In some cases, an additional ingredient, such as vitamin B12, may be added. Compounded tirzepatide is legal, widely available through state-licensed compounding pharmacies, and often less expensive than brand-name versions.

    Is Compounded Tirzepatide the Same as the Brand?

    While compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound, there are some important differences:

    • FDA-approved tirzepatide undergoes rigorous clinical testing and quality control. Compounded tirzepatide is not FDA-approved because it has not undergone the same review process, despite containing the same active peptide.

    • Compounding pharmacies may prepare tirzepatide in different concentrations or delivery forms (such as multi-dose vials instead of prefilled pens).

    • Quality may vary depending on the pharmacy. Patients should always obtain compounded tirzepatide from reputable, state-licensed pharmacies.

    • In October 2024, the tirzepatide shortage was resolved, which limited compounding to patient-specific needs.

    Why Many Patients Choose Compounded Tirzepatide

    Compounded tirzepatide remains an attractive option for many patients. Cost is a major driver, since Mounjaro and Zepbound can cost more than $1,000 per month without insurance coverage. For uninsured patients or those denied coverage, compounded tirzepatide may be significantly more affordable.

    Others prefer compounded tirzepatide because compounding pharmacies may offer dosing flexibility or added ingredients such as vitamin B12. For these reasons, patients should consult with their providers and always choose a reputable, state-licensed compounding pharmacy.

    Key Takeaways

    • Tirzepatide is a novel twincretin therapy that improves glucose control and promotes weight loss.

    • Compounded versions of tirzepatide were created to provide an option for patients during drug shortages. It contains the same active peptide as the brand versions.

    • FDA-approved products (Mounjaro, Zepbound) are still considered the gold standard for safety and consistency.

    • Patients considering compounded tirzepatide should only obtain it from licensed pharmacies and under close medical supervision.

    Concluding Thoughts

    Tirzepatide is the first medication in a new class of drugs that target both the GLP-1 and GIP pathways. It has dramatically improved the management of type 2 diabetes and obesity.

    Compounded tirzepatide provides an effective alternative for some patients, especially during shortages or when cost is a concern.

    Providers should guide patients through their options — whether FDA-approved brands, insurance assistance programs, or compounded formulations — to ensure that the benefits of tirzepatide are realized safely and effectively.

    References

    Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5

    Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus placebo or active comparators in patients with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol.* 2021;9(12):776-785. doi:10.1016/S2213-8587(21)00274-7. PMID: 34656237. Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025;26(1):31-49. doi:10.1080/14656566.2024.2436595

    Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. doi:10.1007/s40268-013-0005-9

    Liu L, Shi H, Xie M, Sun Y, Nahata MC. Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials. Int J Clin Pharm. 2024;46(6):1268-1280. doi:10.1007/s11096-024-01779-x

    Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66(10):1780-1795. doi:10.1007/s00125-023-05956-x

    Qureshi N, Wesolowicz L, Stievater T, Lin AT. Sterile compounding: clinical, legal, and regulatory implications for patient safety. J Manag Care Spec Pharm. 2014;20(12):1183-1191. doi:10.18553/jmcp.2014.20.12.1183

    Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396. doi:10.1210/clinem/dgaa863

    Timko RJ. Applying Quality by Design Concepts to Pharmacy Compounding. Int J Pharm Compd. 2015;19(6):453-463.

    U.S. Food and Drug Administration. FDA clarifies policies for compounders as the national GLP-1 supply begins to stabilize. Published 2024. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize. Accessed September 24, 2025.

    Precision Telemed Clickable Links
    Compounded Tirzepatide
    Compounded Semaglutide
    Sermorelin Peptide
    NAD+ Injections
    Testosterone Replacement Therapy
    Hair Loss
    Erectile Dysfunction